Your shopping cart is currently empty

(Rac)-Modipafantis an orally available and selective platelet-activating factor receptor (PAFR) antagonist that inhibits PAF-induced aggregation of washed platelets in rabbits, and can be used to study arthritis and ischemia/reperfusion (I/R) in the superior mesenteric artery (SMA) of the rat.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $219 | In Stock | In Stock | |
| 5 mg | $548 | In Stock | In Stock | |
| 10 mg | $792 | In Stock | In Stock | |
| 25 mg | $1,220 | In Stock | In Stock | |
| 50 mg | $2,380 | In Stock | In Stock |
| Description | (Rac)-Modipafantis an orally available and selective platelet-activating factor receptor (PAFR) antagonist that inhibits PAF-induced aggregation of washed platelets in rabbits, and can be used to study arthritis and ischemia/reperfusion (I/R) in the superior mesenteric artery (SMA) of the rat. |
| In vivo | In anesthetized guinea pigs, (Rac)-Modipafant(UK-74505) at 30 and 100 μg/kg intravenously inhibited the bronchoconstrictor response to aerosolized PAF without affecting blood pressure or heart rate; oral (Rac)-Modipafant(UK-74505) inhibited the increase in permeability of rat skin vessels to intradermal PAF with an ED50 of 280 +/- 5 μg/kg; and in conscious dogs, complete inhibition of PAF-induced whole blood aggregation occurred in vitro for at least 14 hours following an oral dose of (Rac)-Modipafant(UK-74505)(75 μg/kg).[2] |
| Synonyms | UK-74505, UK74505, UK 74505, Modipafant racemate |
| Molecular Weight | 605.09 |
| Formula | C34H29ClN6O3 |
| Cas No. | 122956-68-7 |
| Smiles | O=C(OCC)C1=C(NC(=C(C(=O)NC2=NC=CC=C2)C1C=3C=CC=CC3Cl)C)C=4C=CC(=CC4)N5C(=NC=6C=NC=CC65)C |
| Relative Density. | 1.34g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (66.11 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.31 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.